- \n
- Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands<\/i><\/b><\/li>\n
- Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM <\/sup>(oveporexton) in China, setting the foundation for next wave of medicines<\/i><\/b><\/li>\n
- No change to FY2026 full-year forecast and management guidance<\/i><\/b><\/li>\n<\/ul>\n
OSAKA, Japan–(BUSINESS WIRE<\/a>)–
\nTakeda (TOKYO:4502\/NYSE:TAK<\/a><\/span>) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year.<\/p>\nFY2026 First Quarter Highlights<\/b><\/p>\n
- \n
- \nRevenue increased by +10.2% versus the prior-year period on an actual exchange rate (AER) basis and decreased by -0.5% on a Constant Exchange Rate (CER) basis as the negative impact of the loss of exclusivity of VYVANSE\u00ae was largely offset by growth from core in-line brands.<\/p>\n<\/li>\n
- \nCore Operating Profit increased by +11.5% on an AER basis and decreased by -0.5% on a CER basis, reflecting continued growth investments supported by the transformation program.<\/p>\n<\/li>\n
- \nReported Operating Profit increased by +9.1% on an AER basis.<\/p>\n<\/li>\n
- \nCore EPS increased by +1.5% at AER and decreased by -11.8% at CER, while Reported EPS decreased by -9.8% YoY.<\/p>\n<\/li>\n
- \nAdjusted Free Cash Flow amounted to JPY 68.6 billion.<\/p>\n<\/li>\n
- \nLaunch preparations for key late-stage pipeline assets (ORZEYFUL, rusfertide and zasocitinib) are progressing on schedule, with the first approval for ORZEYFUL achieved in China.<\/p>\n<\/li>\n
- \nFY2026 full-year outlook remains unchanged.<\/p>\n<\/li>\n
- \nA Capital Markets Day will be held on December 11, 2026, in Tokyo, Japan.<\/p>\n<\/li>\n<\/ul>\n
Takeda President and Chief Executive Officer, Julie Kim, commented:
\n
<\/b>\u201cOur solid performance this quarter marks a good start to the fiscal year and keeps us on track to achieve our full-year targets.<\/p>\n\n\u201cThis quarter\u2019s results reflect our unwavering commitment to financial discipline and the progressing execution of our enterprise transformation. The efficiencies unlocked by this ongoing program are directly fueling our highest priorities in Horizon One in our two-horizon growth strategy: the successful launch of three medicines that have the potential to be blockbuster brands, the advancement of our late-stage pipeline, the enduring resilience of our core in-line portfolio and new capabilities and efficiencies gained through transformation. We look forward to sharing the detailed strategic roadmap for these two growth horizons at our Capital Markets Day in December.\u201d<\/p>\n
Takeda Chief Financial Officer, Milano Furuta, commented:
\n
<\/b>\u201cOur first-quarter performance is tracking consistently with management guidance, with the resilience of our core in-line brands largely offsetting our mature portfolio decline, and OPEX savings through the transformation program being strategically reinvested to fund future growth opportunities. Our full-year forecast and guidance remain unchanged.\u201d<\/p>\nFINANCIAL HIGHLIGHTS for First Quarter Results ended June 30, 2026<\/b><\/p>\n
- Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM <\/sup>(oveporexton) in China, setting the foundation for next wave of medicines<\/i><\/b><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260727883646\/en\/791321\/3\/logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n